3
Views
0
CrossRef citations to date
0
Altmetric
Biotechnology & Immunology

Patent Evaluation: The Use of Interleukin-10 in Adoptive Immunotherapy of Cancer

Pages 1861-1862 | Published online: 02 Mar 2011
 

Summary

Novelty: A method for using interleukin-10 (IL-10) and its compositions in adoptive immunotherapy of human cancers is claimed. Tumour-infiltrating lymphocytes are cultured in the presence of IL-2 and IL-10 so that the tumour-infiltrating lymohocytes proliferate. The cultured tumour-infiltrating lymphocytes (TIL) are then administered to the patient followed by an effective amount of IL-2 and IL-10. The method may reduce side-effects caused by IL-2-induced cytokine production.

Biology: The differential effects of IL-4 and IL-10 on IL-2-induced interferon-γ synthesis and cytoxicity in human NK cells were assayed. The results are presented in figures. Both IL-4 and IL-10 (human or viral) suppressed IFNγ and tumour necrosis factor-α synthesis by IL-2-stimulated peripheral blood mononuclear cells. However, only IL-4 inhibited IL-2 induced lymphokine-activated killer activity. No in vivo data are provided.

Chemistry: IL-10 is preferably selected from polypeptides exoded by the open reading frames defined by cDNA inserts of pPH5C, pH15C and pBCRF1 (SRα). Expression of cDNA was by standard methods. Full sequence details are provided.

Reprints and Corporate Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

To request a reprint or corporate permissions for this article, please click on the relevant link below:

Academic Permissions

Please note: Selecting permissions does not provide access to the full text of the article, please see our help page How do I view content?

Obtain permissions instantly via Rightslink by clicking on the button below:

If you are unable to obtain permissions via Rightslink, please complete and submit this Permissions form. For more information, please visit our Permissions help page.